Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma

Long-term Outcomes After Treatment for Superficial Esophageal Squamous Cell Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02908204

Enrollment

1800

Registered

2016-09-20

Start date

2016-10-31

Completion date

Unknown

Last updated

2016-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Neoplasms

Keywords

superficial esophageal squamous cell carcinoma, efficacy, survival

Brief summary

Tumor is the primary public health problem and the incidence of esophageal cancer showed the increasing trend in the past thirty years. According to the statistics in 2015, the new onset of esophageal cancer is about 477,900 yearly. The mainly pathologic type of esophageal cancer in China is esophageal squamous cell carcinomas, which accounts for more than 90% of patients in China. With the development of endoscopic technics, more and more patients choose to receive the endoscopic procedure rather than traditional surgery. However, the long-term efficacy and outcomes of patients with superficial esophageal squamous cell carcinoma received different interventions remained unclear. Thus, investigators aim to conduct a multi-center retrospective study to investigate the long term outcomes of superficial esophageal squamous cell carcinoma patients receiving endoscopic treatment and surgery.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients received endoscopic treatment because of the superficial esophageal disease and had the pathologic diagnosis of squamous cell carcinoma.

Exclusion criteria

* Combined with other severe disease * With a history of esophageal surgery * Combined with other malignant disease

Design outcomes

Primary

Measure	Time frame
Overall survival	3 years after treatment

Secondary

Measure	Time frame
Recurrence rate	3 years after treatment
Short-term complications incidence rate	30 days after treatment
Long-term complications incidence rate	3 years after treatment

Countries

China

Contacts

Primary ContactShiyao CHEN, PhD

chen.shiyao@zs-hospital.sh.cn13601767310

Outcome results